Stay updated on Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial

Sign up to get notified when there's something new on the Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value (Estimated) on the webpage has recently changed to . This change likely indicates an update or revision in the estimated completion date for a phase II study on poziotinib in treating non-small cell lung cancer with EGFR or HER2 exon 20 mutations.
    Difference
    0.0%
    Check dated 2024-05-10T08:24:38.000Z thumbnail image
  7. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage related to the estimated primary completion date and study completion date has been updated from October 6, 2023, to May 8, 2024. This change indicates a shift in the expected timeline for the completion of the study on Poziotinib in treating patients with non-small lung cancer with specific mutations.
    Difference
    0.9%
    Check dated 2024-05-09T02:09:44.000Z thumbnail image
  8. Check
    18 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:32:50.000Z thumbnail image

Stay in the know with updates to Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Clinical Trial page.